A Phase 3 interventional study of SOF/VEL and SOF in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 76 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 7th largest by enrollment, is one of 11 that started in 2014, is one of 30 in phase 3, and was the 28th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 558 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 6th largest by enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2014, is one of 35 in phase 3, and was the 55th registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to evaluate the safety and tolerability of each treatment regimen in participants with chronic genotype 3 hepatitis C virus (HCV) infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF/VEL FDC for 12 weeks
Drug: SOF/VEL
SOF+RBV for 24 weeks
Drug: SOF · Drug: RBV
Drug pages: Sofosbuvir · Velpatasvir
400/100 mg FDC tablet administered orally once daily
Also known as: Epclusa®, GS-7977/GS-5816
400 mg tablet administered orally once daily
Also known as: Sovaldi®, GS-7977, PSI-7977
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame: Up to 24 weeks
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
SVR4 and SVR24 are defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug.
Time frame: Posttreatment Weeks 4 and 24
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Percentage of Participants With Virologic Failure
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
Time frame: Up to Posttreatment Week 24
Participants were enrolled at study sites in Australia, North America, Europe, and New Zealand. The first participant was screened on 14 July 2014. The last study visit occurred on 15 December 2015.
| Milestone | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Started | 278 | 280 |
| Completed | 258 | 224 |
| Not completed | 20 | 56 |
| Withdrew: Randomized but never treated | 1 | 5 |
| Withdrew: Lack of efficacy | 9 | 30 |
| Withdrew: Lost to follow-up | 8 | 8 |
| Withdrew: Withdrew consent | 2 | 5 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Death | 0 | 3 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 95.3 (92.1 to 97.5) | 80.7 (75.6 to 85.2) |
| percentage of participants | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | 0 | 3.3 |
SVR4 and SVR24 are defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug.
| percentage of participants | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| SVR4 | 96.8 (93.9 to 98.5) | 82.2 (77.1 to 86.5) |
| SVR24 | 95.3 (92.1 to 97.5) | 80.7 (75.6 to 85.2) |
| percentage of participants | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Week 1 (SOF/VEL: N = 277; SOF+RBV: N = 275) | 18.4 (14.0 to 23.5) | 17.5 (13.2 to 22.5) |
| Week 2 (SOF/VEL: N = 276; SOF+RBV: N = 274) | 62.0 (55.9 to 67.7) | 50.0 (43.9 to 56.1) |
| Week 4 (SOF/VEL: N = 276; SOF+RBV: N = 272) | 91.7 (87.8 to 94.6) | 88.2 (83.8 to 91.8) |
| Week 6 (SOF/VEL: N = 276; SOF+RBV: N = 269) | 96.7 (93.9 to 98.5) | 98.9 (96.8 to 99.8) |
| Week 8 (SOF/VEL: N = 276; SOF+RBV: N = 269) | 99.6 (98.0 to 100.0) | 99.3 (97.3 to 99.9) |
| Week 10 (SOF/VEL: N = 276; SOF+RBV: N = 268) | 100.0 (98.7 to 100.0) | 99.3 (97.3 to 99.9) |
| Week 12 (SOF/VEL: N = 275; SOF+RBV: N = 265) | 100.0 (98.7 to 100.0) | 99.6 (97.9 to 100.0) |
| Week 16 (SOF/VEL: N = 0; SOF+RBV: N = 262) | NA (NA to NA) | 98.9 (96.7 to 99.8) |
| Week 20 (SOF/VEL: N = 0; SOF+RBV: N = 260) | NA (NA to NA) | 99.6 (97.9 to 100.0) |
| Week 24 (SOF/VEL: N = 0; SOF+RBV: N = 255) | NA (NA to NA) | 100.0 (98.6 to 100.0) |
| log10 IU/mL | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Change at Wk 1 (SOF/VEL: N =272; SOF+RBV: N =268) | -4.26 ± 0.644 | -4.16 ± 0.640 |
| Change at Wk 2 (SOF/VEL: N =274; SOF+RBV: N =272) | -4.82 ± 0.769 | -4.79 ± 0.702 |
| Change at Wk 4 (SOF/VEL: N =276; SOF+RBV: N =270) | -5.02 ± 0.776 | -5.09 ± 0.699 |
| Change at Wk 6 (SOF/VEL: N =275; SOF+RBV: N =269) | -5.06 ± 0.718 | -5.13 ± 0.712 |
| Change at Wk 8 (SOF/VEL: N =276; SOF+RBV: N =269) | -5.07 ± 0.728 | -5.13 ± 0.712 |
| Change at Wk 10 (SOF/VEL: N =276; SOF+RBV: N =267) | -5.07 ± 0.723 | -5.14 ± 0.710 |
| Change at Wk 12 (SOF/VEL: N =275; SOF+RBV: N =264) | -5.08 ± 0.721 | -5.14 ± 0.711 |
| Change at Wk 16 (SOF/VEL: N = 0; SOF+RBV: N = 262) | NA ± NA | -5.11 ± 0.765 |
| Change at Wk 20 (SOF/VEL: N = 0; SOF+RBV: N = 259) | NA ± NA | -5.14 ± 0.715 |
| Change at Wk 24 (SOF/VEL: N = 0; SOF+RBV: N = 255) | NA ± NA | -5.14 ± 0.715 |
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
| percentage of participants | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| Percentage of Participants With Virologic Failure | 4.0 | 14.2 |
Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF/VEL 12 Weeks | — | 6/277 (2.2%) | 216/277 (78%) |
| SOF+RBV 24 Weeks | — | 15/275 (5.5%) | 243/275 (88.4%) |
| Event | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| DeathGeneral disorders | 0/277 | 1/275 |
| CellulitisInfections and infestations | 0/277 | 1/275 |
| Lung infectionInfections and infestations | 0/277 | 1/275 |
| Propionibacterium infectionInfections and infestations | 0/277 | 1/275 |
| Forearm fractureInjury, poisoning and procedural complications | 0/277 | 1/275 |
| Gun shot woundInjury, poisoning and procedural complications | 0/277 | 1/275 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/277 | 1/275 |
| BursitisMusculoskeletal and connective tissue disorders | 0/277 | 1/275 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/277 | 1/275 |
| Cerebrovascular accidentNervous system disorders | 0/277 | 1/275 |
| Event | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks |
|---|---|---|
| FatigueGeneral disorders | 71/277 | 105/275 |
| HeadacheNervous system disorders | 90/277 | 90/275 |
| InsomniaPsychiatric disorders | 32/277 | 74/275 |
| NauseaGastrointestinal disorders | 47/277 | 58/275 |
| IrritabilityPsychiatric disorders | 23/277 | 40/275 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/277 | 35/275 |
| PruritusSkin and subcutaneous tissue disorders | 8/277 | 35/275 |
| NasopharyngitisInfections and infestations | 34/277 | 33/275 |
| DyspepsiaGastrointestinal disorders | 9/277 | 30/275 |
| AstheniaGeneral disorders | 16/277 | 26/275 |
Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.
| Age, Continuous(years) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Mean | 49 ± 10.4 | 50 ± 10.0 | 50 ± 10.2 |
| Sex: Female, Male(Participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Female | 107 | 101 | 208 |
| Male | 170 | 174 | 344 |
| Ethnicity (NIH/OMB)(Participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 11 | 22 |
| Not Hispanic or Latino | 266 | 263 | 529 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Black or African American | 3 | 1 | 4 |
| White | 250 | 239 | 489 |
| Asian | 23 | 29 | 52 |
| American Indian or Alaska Native | 1 | 3 | 4 |
| Native Hawaiian or Pacific Islander | 0 | 2 | 2 |
| Not Disclosed | 0 | 1 | 1 |
| Region of Enrollment(participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| New Zealand | 9 | 8 | 17 |
| Canada | 15 | 18 | 33 |
| United States | 60 | 60 | 120 |
| Italy | 7 | 11 | 18 |
| United Kingdom | 58 | 47 | 105 |
| Australia | 49 | 44 | 93 |
| France | 48 | 52 | 100 |
| Germany | 31 | 35 | 66 |
| HCV Genotype(participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Genotype 3 (No Confirmed Subtype) | 9 | 18 | 27 |
| Genotype 3a | 265 | 250 | 515 |
| Genotype 3b | 2 | 5 | 7 |
| Genotype 3h | 0 | 2 | 2 |
| Genotype 3k | 1 | 0 | 1 |
| Cirrhosis Status(participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| Yes | 80 | 83 | 163 |
| No | 197 | 187 | 384 |
| Missing | 0 | 5 | 5 |
| IL28b Status(participants) | SOF/VEL 12 Weeks | SOF+RBV 24 Weeks | Total |
|---|---|---|---|
| CC | 105 | 111 | 216 |
| CT | 148 | 133 | 281 |
| TT | 24 | 31 | 55 |
3 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
The record gives a start of Jul 2014, a primary completion of Sep 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin